In 2023, results were published from arm E of the study, evaluating the combination of Teliso-V and osimertinib in patients with EGFR-mutant, c-MET protein-overexpressing, osimertinib-resistant NSCLC [97]. The gene discussed is MET; the disease is non-small cell lung carcinoma.